Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV
作者:Mark J. Mitton-Fry、Steven J. Brickner、Judith C. Hamel、Rose Barham、Lori Brennan、Jeffrey M. Casavant、Xiaoyuan Ding、Steven Finegan、Joel Hardink、Thuy Hoang、Michael D. Huband、Meghan Maloney、Anthony Marfat、Sandra P. McCurdy、Dale McLeod、Chakrapani Subramanyam、Michael Plotkin、Usa Reilly、John Schafer、Gregory G. Stone、Daniel P. Uccello、Todd Wisialowski、Kwansik Yoon、Richard Zaniewski、Christopher Zook
DOI:10.1016/j.bmcl.2017.06.009
日期:2017.8
Novel (non-fluoroquinolone) inhibitors of bacterial type II topoisomerases (NBTIs) are an emerging class of antibacterial agents. We report an optimized series of cyclobutylaryl-substituted NBTIs. Compound 14 demonstrated excellent activity both in vitro (S. aureus MIC90 = 0.125 μg/mL) and in vivo (systemic and tissue infections). Enhanced inhibition of Topoisomerase IV correlated with improved activity
细菌II型拓扑异构酶(NBTI)的新型(非氟喹诺酮)抑制剂是一类新兴的抗菌剂。我们报告了一系列优化的环丁基芳基取代的NBTIs。化合物14在体外(金黄色葡萄球菌MIC 90 = 0.125μg/ mL)和体内(全身和组织感染)均显示出优异的活性。拓扑异构酶IV的增强抑制作用与金黄色葡萄球菌菌株的活性提高有关,这些菌株具有赋予NBTI抗性的突变。在麻醉的豚鼠模型中,化合物14还显示出85.9μM的改进的hERG IC 50和良好的分布。